Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate.

McCormick DL, Rao KV, Johnson WD, Bosland MC, Lubet RA, Steele VE.

Cancer Prev Res (Phila). 2010 Mar;3(3):381-92. doi: 10.1158/1940-6207.CAPR-09-0176. Epub 2010 Feb 9.

2.

Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.

Lee JI, Nian H, Cooper AJ, Sinha R, Dai J, Bisson WH, Dashwood RH, Pinto JT.

Cancer Prev Res (Phila). 2009 Jul;2(7):683-93. doi: 10.1158/1940-6207.CAPR-09-0047.

3.

Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.

Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW.

J Clin Oncol. 2009 Aug 1;27(22):3577-83. doi: 10.1200/JCO.2008.18.8938. Epub 2009 Jun 15.

4.

Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.

5.

The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis.

El-Bayoumy K.

Nutr Cancer. 2009;61(3):285-6. doi: 10.1080/01635580902892829. No abstract available.

PMID:
19373601
6.

Potential stages for prostate cancer prevention with selenium: implications for cancer survivors.

Facompre N, El-Bayoumy K.

Cancer Res. 2009 Apr 1;69(7):2699-703. doi: 10.1158/0008-5472.CAN-08-4359. Epub 2009 Mar 24. Review.

7.

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr.

JAMA. 2009 Jan 7;301(1):39-51. doi: 10.1001/jama.2008.864. Epub 2008 Dec 9.

8.

Effects of naturally occurring and synthetic organoselenium compounds on protein profiling in androgen responsive and androgen independent human prostate cancer cells.

Sinha R, Pinto JT, Facompre N, Kilheffer J, Baatz JE, El-Bayoumy K.

Nutr Cancer. 2008;60(2):267-75. doi: 10.1080/01635580701630479.

PMID:
18444160
9.

Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite.

Li GX, Lee HJ, Wang Z, Hu H, Liao JD, Watts JC, Combs GF Jr, Lü J.

Carcinogenesis. 2008 May;29(5):1005-12. doi: 10.1093/carcin/bgn007. Epub 2008 Feb 28.

10.

Inhibition of nuclear factor-kappaB DNA binding by organoselenocyanates through covalent modification of the p50 subunit.

Chen KM, Spratt TE, Stanley BA, De Cotiis DA, Bewley MC, Flanagan JM, Desai D, Das A, Fiala ES, Amin S, El-Bayoumy K.

Cancer Res. 2007 Nov 1;67(21):10475-83.

11.
12.
13.
14.
15.

Mechanisms of selenium down-regulation of androgen receptor signaling in prostate cancer.

Chun JY, Nadiminty N, Lee SO, Onate SA, Lou W, Gao AC.

Mol Cancer Ther. 2006 Apr;5(4):913-8.

16.
17.

Delineating the mechanism by which selenium deactivates Akt in prostate cancer cells.

Wu Y, Zu K, Warren MA, Wallace PK, Ip C.

Mol Cancer Ther. 2006 Feb;5(2):246-52.

19.
20.

PKB/AKT and ERK regulation of caspase-mediated apoptosis by methylseleninic acid in LNCaP prostate cancer cells.

Hu H, Jiang C, Li G, Lü J.

Carcinogenesis. 2005 Aug;26(8):1374-81. Epub 2005 Apr 21.

Items per page

Supplemental Content

Write to the Help Desk